Over the last few years there has been a shift in conducting clinical trials away from North America and Europe and towards emerging markets, particularly the BRIC countries. Although the shift to perform clinical trials in these BRIC countries has increased, the majority of the drugs are still manufactured in North America or Europe. Rachel Griffiths at Biotec Services International explains why drug companies have been nervous to move new drug manufacturing to these countries, and how Brazil and India are expanding their development pharmaceutical manufacturing capability.
[prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/06/2-Clinical-Supply-in-Emerging-Markets.pdf” type=”pdf”]Clinical Supply in Emerging Markets[/prettyfilelink]
http://ipimediaworld.com/wp-content/uploads/2013/06/2-Clinical-Supply-in-Emerging-Markets.pdf